HSPG2 and cardiac hypertrophy: PLC and α- and β-adrenergic signalling pathways are all known to be affected by or implicated in cardiac hypertrophy (44–46), while the expression of myosin heavy chains is also known to be altered in hypertrophic or failing hearts (47,48).